Develops cancer therapies, including antibodies and antibody drug conjugates.
Dec 2025Revenue $10.8M/yrExpenses $163M/yr
Fell below break-even Apr 2013Cash runway ≈ 2.3 years from Jun 2026
Figures by year
When will Crescent Biopharma be profitable again?
Its expenses passed its revenue in Apr 2013. In the 12 months to Dec 2025, revenue was $10.8M and expenses $163M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $10.8M | $163M | −$153M |
| Dec 2023 | $10.0K | $39.3M | −$39.3M |
| Dec 2022 | $75.0K | $47.5M | −$47.4M |
| Dec 2021 | $1.16M | $64.6M | −$63.4M |
| Dec 2020 | $10.2M | $61.7M | −$51.5M |
| Dec 2016 | $18.5K | $31.9M | −$31.9M |
| Dec 2015 | $20.1M | $32.9M | −$12.8M |
| Dec 2014 | $15.0M | $26.2M | −$11.1M |
| Dec 2013 | $3.99M | $14.6M | −$10.6M |
| Dec 2012 | $15.3M | $11.6M | $3.64M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.